RFK Jr. has turned the CDC into ‘a zombie organization’

HHS Secretary Robert F. Kennedy Jr. has overseen an Advisory Committee on Immunization Practices that advised the CDC to withdraw its universal newborn Hepatitis B vaccination recommendation and limit birth doses to infants of infected mothers, a move that infectious-disease experts say risks reversing the policy that cut pediatric Hep B infections by 99% since 1991. Kennedy has also removed prior ACIP members, curtailed COVID and MMR guidance for children, opposed measles mandates, ended a hospital reimbursement rule tied to staff vaccination rates, cut $500 million for mRNA vaccine development and funded no-bid research into vaccine‑autism links—actions critics contend have undermined CDC credibility and public‑health protections. The article warns these changes could have material public‑health and economic consequences given a Lancet study estimating vaccines have saved 154 million lives and will prevent hundreds of millions of illnesses and trillions in costs, and points to recent measles outbreaks as an early indicator of increased risk from declining vaccination coverage.

Analysis

The article reports that HHS Secretary Robert F. Kennedy Jr.'s Advisory Committee on Immunization Practices advised withdrawing the CDC's long-standing universal newborn Hepatitis B vaccination recommendation and limiting birth doses to infants of infected mothers; the piece notes pediatric Hep B infections fell 99% since universal vaccination began in 1991 and that harmful side effects are "extremely rare." It highlights that roughly 70% of Americans with Hepatitis B are unaware of their infection, 14% of pregnant women are not tested before delivery, and Hepatitis B can be transmitted by everyday contact, underlining the public-health rationale for universal birth dosing.

Kennedy has also removed prior ACIP members and curtailed vaccine guidance: restricting COVID-shot recommendations to seniors and high-risk individuals, removing combined MMR for under-fours, ending a hospital reimbursement rule tied to staff vaccination rates, cutting $500 million for mRNA vaccine development, and funding no-bid contracts to study vaccine-autism links. Critics quoted in the article characterize these actions as undermining CDC credibility; a recent South Carolina measles outbreak—where most infected children were unvaccinated—is cited as an early indicator of risk.

The article cites a Lancet study estimating vaccines saved 154 million lives since 1974 and will prevent 508 million U.S. illnesses and save $540 billion in direct costs (and $2.7 trillion societally) for children born 1994–2023, framing potential economic consequences if coverage falls. Market signals included with the article show strongly negative sentiment and a modest market-impact score (0.25), implying reputational and regulatory risk to vaccine- and public-health‑exposed entities rather than immediate broad market disruption.

Key Decisions for Investors

• Reassess and potentially hedge or trim direct exposure to vaccine developers and mRNA-platform biotechs that rely on U.S. federal funding or HHS contracts given the reported $500 million cut and policy uncertainty
• Monitor hospital operators and health insurers for changes in utilization and reimbursement flows after the removal of vaccination-linked federal incentives and in light of reported measles outbreaks and potential Hepatitis B resurgence
• Increase tracking of ACIP guidance, state-level outbreak data, and congressional/regulatory actions as near-term catalysts that could prompt rapid re-rating of healthcare and public-health contractors, maintain liquidity to reposition quickly
• Consider selective, risk‑managed exposure to diagnostics, therapeutics, and hospital-capacity names that could see higher demand if vaccination coverage declines, but size positions conservatively given political and reputational uncertainty